Trial Profile
A retrospective study assessing the efficacy of Apremilast in lupus rashes refractory to conventional treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jun 2019
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Discoid lupus erythematosus; Systemic lupus erythematosus
- Focus Therapeutic Use
- 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism
- 24 Oct 2018 Results assessing apremilast for the treatment of refractory skin lupus lesions, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
- 14 Jul 2018 New trial record